Monitoring and Management of Antifungal Therapy

Introduction to Monitoring

Patients on antifungal therapy should be monitored for liver function tests, renal function, drug interactions, clinical response, and potential adverse effects throughout therapy, as recommended by the Infectious Diseases Society of America 1

Complete liver function tests and renal function tests should be performed at baseline, and liver function tests should be repeated at day 7-14, with ongoing monitoring every 2-4 weeks for extended therapy 1
Renal function should be assessed at baseline and clinically indicated, with dose adjustments based on renal function:
CrCl (mL/min) Recommended Dose
>50 100% of recommended dose
21-50 50% of recommended dose
<20 25% of recommended dose

Clinical symptoms of fungal infection should be evaluated, and for systemic infections, monitoring for resolution of fever and other signs of infection is crucial, with continuation of therapy until all signs, symptoms, and CSF abnormalities have resolved, as per the Infectious Diseases Society of America 1
For candidiasis, clinical improvement of symptoms specific to the infection site should be assessed, following guidelines from the Infectious Diseases Society of America 3
Fluconazole has limited activity against C. krusei and C. glabrata, and no activity against Aspergillus species, as reported by the Clinical Infectious Diseases journal 3

For patients on continuous renal replacement therapy (CVVH/CVVHDF), more aggressive monitoring is necessary due to increased fluconazole clearance, and therapeutic drug monitoring should be considered if available 4
For immunocompromised patients, monitoring for breakthrough fungal infections, particularly those not covered by fluconazole, and consideration of antigen testing for persistent infections are essential, as recommended by the Infectious Diseases Society of America 4
The choice of fluconazole dose should consider the type of fungal risk, with 200-400 mg daily effective for Candida prophylaxis, and itraconazole 200 mg daily preferred over fluconazole for regions with high histoplasmosis risk, according to the Infectious Diseases Society of America 2, 4

Failure to adjust dose for renal impairment can lead to toxicity, and inadequate duration of therapy can result in relapse, emphasizing the importance of proper monitoring and management, as highlighted by the Infectious Diseases Society of America 1, 3
Inadequate dosing can lead to breakthrough infections, and failure to adjust for renal function can result in subtherapeutic doses, as reported by the National Kidney Foundation 2
Drug interactions with immunosuppressants, anticonvulsants, and other medications can occur, and overreliance on fluconazole can lead to emergence of resistant fungal strains, as warned by the Infectious Diseases Society of America 3

The recommended prophylactic dose of fluconazole in immunocompromised patients is 400 mg daily for bone marrow transplant recipients and 200-400 mg daily for other immunocompromised patients, with dose adjustments based on specific risk factors and renal function, as suggested by the Infectious Diseases Society of America 2
For patients with cryptococcal meningitis prevention, 200 mg daily is recommended for patients with CD4 count <100/μL, and should be continued until CD4 >100/μL and undetectable viral load sustained for 3 months, according to the Centers for Disease Control and Prevention 2, 5
Fluconazole prophylaxis should be avoided in patients with prior azole exposure, and monitoring for breakthrough infections is essential, particularly for molds not covered by fluconazole, as recommended by the Centers for Disease Control and Prevention 3
The duration of fluconazole prophylaxis should be based on immunosuppression intensity for solid organ transplant patients, as suggested by the American Society of Transplantation 2
For bone marrow transplant, fluconazole prophylaxis should be continued throughout the neutropenic period, as suggested by the American Society of Hematology 2
For HIV/AIDS, fluconazole prophylaxis should be continued until immune reconstitution, as recommended by the Centers for Disease Control and Prevention 2, 5